MWAI (MedWellAI) YoY EBITDA Growth: 74.07% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MWAI MedWellAI Inc MWAI
6 GF Score
Price $0.35
! 4 Warning Signs
View Full Analysis

What is MedWellAI YoY EBITDA Growth?

MedWellAI MWAI +0.57% 6 YoY EBITDA Growth is 74.07% as of Mar. 2026. GuruFocus rates MWAI with a GF Score™ of 6/100. The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. MedWellAI's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 74.07%.

MedWellAI's EBITDA per Share for the three months ended in Mar. 2026 was $-0.04.

MedWellAI YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for MedWellAI's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedWellAI YoY EBITDA Growth Chart

MedWellAI Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6,585.26 103.53 -1,571.21 78.60 75.58

MedWellAI Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -345.45 58.97 28.35 26.32 74.07
MWAI
6GF Score
MedWellAI Inc MWAI
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedWellAI YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

MedWellAI's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.502--2.056)/ | -2.056 |
=75.58 %

MedWellAI's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.035--0.135)/ | -0.135 |
=74.07 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 74.07% mean?
MedWellAI (MWAI) has a YoY EBITDA Growth of 74.07% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MedWellAI and its competitors.
Is MedWellAI's YoY EBITDA Growth too high?
MedWellAI's current YoY EBITDA Growth is 74.07%. Overall, MedWellAI has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does MedWellAI's YoY EBITDA Growth compare to PMAX and PWCM?
MedWellAI's YoY EBITDA Growth of 74.07% can be compared against companies in the Capital Markets industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Capital Markets company?
A good YoY EBITDA Growth depends on the Capital Markets industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MedWellAI and its competitors. MedWellAI's current YoY EBITDA Growth is 74.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedWellAI stock overvalued right now?
MedWellAI (MWAI) has a current YoY EBITDA Growth of 74.07%. The current YoY EBITDA Growth is 74.07%. MedWellAI's overall GF Score™ is 6/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For MedWellAI (MWAI), the current YoY EBITDA Growth is 74.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MedWellAI Business Description

Address 2380 Drew Street, Suite 3, Clearwater, FL, USA, 33765
MedWellAI Inc is a holding company focused on AI-driven healthcare and wellness solutions, offering a B2B platform for GLP medications with real-time inventory and provider support. The company operates as a single operating segment, focusing on acquiring, launching, and operating companies in the rapidly growing health and wellness sector.
6GF Score

Get the complete analysis for MWAI

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price